Altimmune Z Score
ALT  Stock  USD 9.09 0.22 2.36% 
Altimmune  Z Score 
Altimmune Z Score Analysis
Altimmune's ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 
 
 
 

Altimmune Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Altimmune is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Altimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Altimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Altimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
In accordance with the company's disclosures, Altimmune has a Z Score of 0.0. This is 100.0% lower than that of the iShares sector and 100.0% lower than that of the Market Neutral industry. The z score for all United States stocks is 100.0% higher than that of the company.
Altimmune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (1.55 M)  (1.45 M)  (820.8 K)  (1.14 M)  (2.07 M)  (2.12 M)  
Revenue Per Employee  357.94 K  382.64 K  232.06 K  189.83 K  93.84 K  96.31 K  
Average Assets  62.24 M  55.15 M  59.45 M  158.72 M  244.32 M  263.61 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (51.87 M)  (45.03 M)  (21.18 M)  (54.52 M)  (96.89 M)  (99.44 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (51.76 M)  (44.72 M)  (20.19 M)  (54.02 M)  (96.53 M)  (99.07 M)  
Earnings before Tax  (52.06 M)  (45.32 M)  (20.58 M)  (54.46 M)  (97.09 M)  (99.65 M)  
Average Equity  45.56 M  41.09 M  52.61 M  136.75 M  224.03 M  241.72 M  
Enterprise Value  14.64 M  11.5 M  18.09 M  229.51 M  189.11 M  151.82 M  
Free Cash Flow  (20.37 M)  (10.39 M)  (9.6 M)  (34.51 M)  (90.36 M)  (92.73 M)  
Invested Capital  8.21 M  2.09 M  28.41 M  104.32 M  (2.17 M)  (2.22 M)  
Invested Capital Average  4.58 M  3.32 M  16.28 M  54.88 M  45.09 M  48.65 M  
Market Capitalization  31.15 M  18.04 M  28.99 M  373.04 M  364.01 M  392.74 M  
Tangible Asset Value  24.31 M  40.9 M  41.33 M  232.29 M  206.45 M  222.74 M  
Working Capital  19.63 M  34.84 M  35.47 M  218.24 M  185.85 M  200.52 M 
Altimmune Institutional Holders
Institutional Holdings refers to the ownership stake in Altimmune that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Altimmune's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in highprofile magazines, and presentations at investor conferences help move the stock higher, increasing Altimmune's value.Security Type  Shares  Value  
Xtx Topco Ltd  Common Shares  19.7 K  120 K  
Xtx Topco Ltd  Common Shares  14.8 K  135 K  
Woodline Partners Lp  Common Shares  550.7 K  6.4 M  
Woodline Partners Lp  Common Shares  846.6 K  5.2 M  
Woodline Partners Lp  Common Shares  620.7 K  5.7 M  
Woodline Partners Lp  Common Shares  348.8 K  3.9 M  
Wolverine Trading Llc  Common Shares  24.1 K  284 K  
Wolverine Trading Llc  Call Options  29.8 K  351 K  
Wolverine Trading Llc  Put Options  41.6 K  371 K 
Fund Asset Allocation for Altimmune
The fund invests 21.57% of asset under management in tradable equity instruments, with the rest of investments concentrated in bonds (15.26%) and various exotic instruments.
Value 
Instrument Type 
Altimmune Fundamentals
Return On Equity  (44.49) %  
Return On Asset  (24.85) %  
Current Valuation  366.1 M  
Shares Outstanding  39.74 M  
Shares Owned by Insiders  0.71 %  
Shares Owned by Institutions  82.27 %  
Number of Shares Shorted  7.05 M  
Price to Earning  (1.66) X  
Price to Book  1.45 X  
Price to Sales  101.08 X  
Revenue  3.48 M  
Gross Profit  (71.09 M)  
EBITDA  (92.3 M)  
Net Income  (96.94 M)  
Cash and Equivalents  184.76 M  
Cash per Share  3.81 X  
Total Debt  1.33 M  
Debt to Equity  0.006 %  
Current Ratio  14.12 X  
Book Value Per Share  6.11 X  
Cash Flow from Operations  (69.97 M)  
Short Ratio  1.67 X  
Earnings Per Share  (1.91) X  
Number of Employees  47  
Beta  0.47  
Market Capitalization  351.29 M  
Total Asset  29.47 M  
Retained Earnings  (148.22 M)  
Working Capital  5 M  
Current Asset  13.9 M  
Current Liabilities  10.49 M  
Year to Date Return  1.67 %  
One Year Return  (6.49) %  
Three Year Return  (0.57) %  
Net Asset  51.54 M  
Last Dividend Paid  873.01  
Equity Positions Weight  21.57 %  
Bond Positions Weight  15.26 % 
About Altimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Altimmune without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Recommendations Now
Analyst RecommendationsAnalyst recommendations and target price estimates broken down by several categories 
All Next  Launch Module 
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving together with Altimmune
+  0.65  EMSKF  MUSK METALS CORP  Earnings Call This Week  PairCorr 
Moving against Altimmune
  0.77  PILBF  Pilbara Minerals  Downward Rally  PairCorr  
  0.66  SGML  Sigma Lithium Corp  Buyout Trend  PairCorr 
The ability to find closely correlated positions to Altimmune could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Please continue to Altimmune Piotroski F Score and Altimmune Valuation analysis. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on meanvariance optimization algorithm.
Complementary Tools for analysis
When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Idea OptimizerUse advanced portfolio builder with precomputed micro ideas to build optimal portfolio  Go  
Stock TickersUse highimpact, comprehensive, and customizable stock tickers that can be easily integrated to any websites  Go  
Stock TickersUse highimpact, comprehensive, and customizable stock tickers that can be easily integrated to any websites  Go  
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios  Go  
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance  Go  
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities  Go  
Volatility AnalysisGet historical volatility and risk analysis based on latest market data  Go  
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance  Go  
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios  Go 
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 441.4 M  Quarterly Revenue Growth YOY (0.99)  Return On Assets (0.23)  Return On Equity (0.42) 
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.